Resmetirom (Rezdiffra) for Fatty Liver: Who It's For
Rezdiffra is approved for adults with noncirrhotic MASH and F2-F3 fibrosis, not for simple fatty liver. Here is how it works, what trials showed and its limits.
TL;DR
- Resmetirom (Rezdiffra) is a once-daily pill approved in the US (March 2024, accelerated approval) and conditionally in the EU (August 2025) for adults with noncirrhotic MASH and moderate to advanced fibrosis (F2-F3), used with diet and exercise.
- In the main trial, MASH resolved in about 26-30% of people on the drug versus about 10% on placebo, and fibrosis improved by a stage in about 24-26% versus 14%.
- It is not for simple fatty liver or cirrhosis, does not replace lifestyle change, and its long-term benefit on outcomes is still being confirmed.
What Is Resmetirom (Rezdiffra)?
Resmetirom is the first medicine approved specifically to treat MASH, the inflamed, scarring form of MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD). The brand name is Rezdiffra. MASH was previously called NASH. Most people with fatty liver do not have it, and do not need a drug. Lifestyle change remains the base of treatment (see how to reverse fatty liver).
Is Rezdiffra Approved? Current Status
As of October 2026, verified against the labels:
- United States. The FDA approved Rezdiffra on March 14, 2024, under accelerated approval, “based on improvement of MASH and fibrosis.” The label states continued approval “may be contingent upon verification and description of clinical benefit in confirmatory trials.” The FDA required a 54-month study to assess clinical benefit.
- European Union. The EU granted a conditional marketing authorisation on August 18, 2025, for adults with noncirrhotic MASH and moderate to advanced fibrosis (F2 to F3), together with diet and exercise. The EMA says the company must provide further data from two ongoing studies.
Conditional or accelerated approval is not a lesser drug, but it means the proof of long-term benefit is still being collected. We found no published results from the confirmatory outcomes trials and no change to the approved indication as of this writing.
Who Is It For?
The FDA indication is adults with noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3). In practice:
| Situation | Rezdiffra? |
|---|---|
| Fatty liver without significant scarring (F0-F1) | Not approved; lifestyle is the treatment |
| MASH with F2-F3 fibrosis, no cirrhosis | The approved group |
| Compensated cirrhosis (F4) | Not approved; trials in this group are ongoing |
| Decompensated cirrhosis | The label says to avoid it |
The EASL–EASD–EASO 2024 guideline says that, where locally approved, adults with noncirrhotic MASH and significant fibrosis (stage 2 or above) should be considered for resmetirom, and that no MASH-targeted drug can currently be recommended for cirrhosis. A liver biopsy is not required by the US label, so doctors often use blood scores and elastography to find candidates (see liver fibrosis stages, FIB-4 calculator and FibroScan results explained).
How Does Resmetirom Work?
It is a thyroid hormone receptor-beta agonist. In the label’s words, thyroid hormone receptor beta is “the major form of THR in the liver, and stimulation of THR-β in the liver reduces intrahepatic triglycerides.” In plain terms, it nudges liver cells to burn and clear more fat. The drug is designed to act mainly in the liver rather than as a general thyroid medicine. The label reports it lowers liver fat measured by MRI-PDFF or CAP, and also lowers liver stiffness, though the clinical relevance of those changes is yet to be confirmed.
What Did the Trials Show?
The pivotal trial, MAESTRO-NASH, was published in the New England Journal of Medicine in 2024. It enrolled adults with biopsy-confirmed NASH and fibrosis stage F1B, F2 or F3, and randomized 966 people in the primary analysis to 80 mg, 100 mg or placebo once daily. The two goals were measured on biopsy at week 52.
| Result at 52 weeks | Resmetirom 80 mg | Resmetirom 100 mg | Placebo |
|---|---|---|---|
| NASH resolution, no worse fibrosis | 25.9% | 29.9% | 9.7% |
| Fibrosis better by 1 stage or more, NASH not worse | 24.2% | 25.9% | 14.2% |
| LDL cholesterol change (week 24) | -13.6% | -16.3% | +0.1% |
| Serious adverse events | 10.9% | 12.7% | 11.5% |
Source: Harrison et al., NEJM 2024.
That is roughly 16 to 20 percentage points more people with resolved MASH, and 10 to 12 more with improved fibrosis, than on placebo. It also means most people, including most of those on the drug, did not reach the goal in one year. The trial continues to see whether longer treatment improves clinical outcomes such as progression to cirrhosis. The EASL guideline adds that liver enzymes and blood lipids fell, while effects on blood sugar control and body weight were neutral.
What Are the Side Effects and Safety Warnings?
From the FDA label:
- Common. Diarrhea, nausea, itching, vomiting, constipation, abdominal pain and dizziness (reported in at least 5% of patients and more often than placebo). Diarrhea and nausea most often began early and were mild to moderate. In the trial, diarrhea was reported at 14, 23 and 33 first events per 100 patient-years on placebo, 80 mg and 100 mg.
- Liver injury. Hepatotoxicity has been observed; liver tests are monitored, and the drug is stopped if it is suspected.
- Gallbladder. Gallstones, acute cholecystitis and gallstone pancreatitis were seen more often with the drug.
- Statins. Resmetirom raises exposure to atorvastatin, pravastatin, rosuvastatin and simvastatin. The label limits rosuvastatin and simvastatin to 20 mg a day, and pravastatin and atorvastatin to 40 mg a day.
- Other interactions. Strong CYP2C8 inhibitors such as gemfibrozil are not recommended, and the dose is reduced with moderate ones such as clopidogrel.
- Liver impairment. Avoid in decompensated cirrhosis (Child-Pugh B or C). Safety and effectiveness in MASH cirrhosis have not been established.
- Pregnancy. There are no human data on use in pregnancy.
How Is It Dosed?
By weight, per the label: 80 mg once daily under 100 kg, and 100 mg once daily at 100 kg or more, with or without food. Tablets are swallowed whole. If you miss a dose, skip it and take the next one on schedule. These are label facts, not instructions; your prescriber sets the dose.
What Doesn’t Resmetirom Do?
- It does not treat simple fatty liver, and it is not a weight-loss drug.
- It does not replace diet and exercise. The label says to use it in conjunction with them, and everyone in the trial received lifestyle counseling. See the fatty liver diet.
- It has not yet proven it prevents cirrhosis, liver cancer, transplant or death. The approval rests on biopsy improvement; outcome data are pending.
- It does not work for everyone. Most people in the trial, including those on the drug, did not reach the main goals at one year.
- It does not treat cirrhosis, alcohol-related liver disease or the other causes of liver damage.
How Does It Compare With GLP-1 Medicines?
Semaglutide (Wegovy) also has approval for MASH with moderate to advanced fibrosis, and works differently, by acting on appetite and metabolism, which usually brings weight loss. Which fits you depends on your weight, diabetes, other medicines and doctor’s judgment. That comparison is covered in Wegovy and GLP-1s for fatty liver.
Questions to Ask Your Doctor
- What is my fibrosis stage, and how was it measured?
- Do I have MASH or simple fatty liver?
- Am I a candidate for resmetirom or a GLP-1 medicine?
- How will you monitor my liver tests and gallbladder?
- Does it interact with my statin or other medicines?
- What diet and activity goals should I keep working on?
The Bottom Line
Resmetirom (Rezdiffra) is a real option for a specific group: adults with noncirrhotic MASH and F2-F3 fibrosis. It improved MASH and fibrosis on biopsy for a meaningful minority more than placebo, with gastrointestinal side effects, gallbladder and liver warnings, and statin dose limits. It is not for simple fatty liver or cirrhosis, does not replace lifestyle change, and its effect on long-term outcomes is still being confirmed. If your scarring tests worry you, ask a hepatologist whether it fits.
Sources
- Rezdiffra (resmetirom) prescribing information, DailyMed (Madrigal Pharmaceuticals)
- FDA: FDA approves first treatment for patients with liver scarring due to fatty liver disease (March 14, 2024)
- European Medicines Agency: Rezdiffra EPAR
- Harrison SA et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (New England Journal of Medicine, 2024)
- EASL–EASD–EASO Clinical Practice Guidelines on the management of MASLD (Journal of Hepatology, 2024)
This article is for informational purposes only and is not medical advice. Talk to your doctor or hepatologist about your specific situation.
Track How This Fits YOUR Liver Diet
Everyone's liver situation is different. Liverly tracks added sugar, saturated fat, calories, and fiber personalized to your diagnosis — including the hidden added-sugar aliases that other trackers miss.
Scan to get Liverly on your phone
Free on iPhone and Android
Frequently Asked Questions
Who can take Rezdiffra (resmetirom)?
The FDA label covers adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) and moderate to advanced liver fibrosis, consistent with stages F2 to F3, used with diet and exercise. It is not approved for simple fatty liver, and the label says to avoid it in decompensated cirrhosis. Whether you qualify depends on your scarring stage, which a hepatologist works out from blood tests, imaging or biopsy.
What dose of Rezdiffra is used?
The FDA label sets the dose by body weight: 80 mg by mouth once daily if you weigh under 100 kg, and 100 mg once daily if you weigh 100 kg or more, with or without food. The dose is lowered with some interacting medicines, and certain statins have dose limits. Your prescriber sets the dose, so do not adjust it yourself.
Does Rezdiffra cure fatty liver or replace diet and exercise?
No. It is approved to be used in conjunction with diet and exercise, not instead of them. In the main trial, 26 to 30 percent of people on the drug had MASH resolution versus about 10 percent on placebo, and about a quarter improved by a fibrosis stage versus 14 percent. Many people did not respond, and benefits on long-term outcomes are still being studied.
What are the side effects of Rezdiffra?
The most common are diarrhea and nausea, usually early in treatment and mild to moderate; others include itching, vomiting, constipation, abdominal pain and dizziness. The label also warns of liver injury and gallbladder problems such as gallstones, so liver tests are monitored. It raises exposure to some statins, so tell your doctor about all medicines you take.